Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Rituximab in Marginal Zone Lymphoma
NCT04268277Phase 2Terminated
- Sponsor
- Ulm University
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in marginal zone lymphoma (MZL), sponsored by Ulm University. Started Mar 2022; status: terminated.
02
Drugs
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04268277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268277.